Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010

May 13, 2010

DIAMOND BAR, California, May 13, 2010 /PRNewswire/ — Biosense Webster,
Inc. will underline its leadership position in the electrophysiology market
and underscore its commitment to electrophysiologists and their catheter
ablation practices at the 2010 Heart Rhythm Meeting. Heart Rhythm is the most
important scientific meeting in the field of Electrophysiology and will be
held in Denver, CO, USA from May 12th to 15th.

This year, Biosense Webster, Inc. will be showcasing its cutting edge
product pipeline and constant innovation. Over the past few months, the
company has launched significant products and ground breaking innovations
into the Electrophysiology marketplace, with the most recent being the
European release of the new ThermoCool(R)SF catheter. In the past few months,
the company has launched its pioneering new 3D mapping platform, the Carto(R)
3 System and NaviStar(R) and Celsius(R) RMT ThermoCool(R) Catheters around
the globe.

“We are gaining significant momentum with our Carto(R) 3 system around
the world,” said Shlomi Nachman, President, Biosense Webster. “Our installed
base is ramping up extremely quickly with EP labs across the globe”. “We are
looking forward to unleashing the true blockbuster potential of the Carto(R)
3 System as more and more labs switch over to the new Carto(R) System
platform and many upgrade from their current Carto(R) XP System.

“The Carto(R) 3 System is an exciting technology that represents a major
step forward for electrophysiologists. I was especially impressed with the
Fast Anatomical Mapping [FAM] feature with the Lasso(R) NAV Circular Variable
Mapping Catheter. I was able to create a map quickly and the accuracy was
excellent,” said Vivek Y. Reddy, M.D., Director, Cardiac Arrhythmia Service,
The Zeng and Michael A. Wiener Cardiovascular Institute, The Marie-Josee and
Henry R. Kravis Center for Cardiovascular Health. Dr. Reddy is also Professor
of Medicine, Mount Sinai School of Medicine in New York City. “In addition, I
was very happy with the way in which the system merged with our CT scans and
my whole lab team definitely enjoys the new quick system set up – the
Connection of Choice(TM), as it is termed, is a breath of fresh air and
allows my team to have access to Biosense Webster’s full line of diagnostic
catheters, including their recently launched new 20 pole diagnostic catheter.”

Biosense Webster also holds the unique and enviable position of being the
only company in the entire field of Electrophysiology with an FDA approved
catheter for Atrial Fibrillation, or AFib as it is more commonly known as.
The NaviStar(R) ThermoCool(R) Catheter, including its bidirectional EZ
Steer(R) Catheter platform, was approved by the US Food & Drug Administration
on February 6th, 2009 for the safe and effective treatment of drug refractory
recurrent symptomatic paroxysmal atrial fibrillation when used with the
Carto(R) System.

The one year data from the Biosense Webster trial was recently published
as the lead article in the January 27th issue of JAMA (Journal of the
American Medical Association) where the study (A comparison of Antiarrhythmic
Drug Therapy and Radiofrequency Catheter Ablation in patients with Paroxysmal
Atrial Fibrillation: A Randomized Controlled Trial by Wilbur et al)
highlighted that patients with the most common heart rhythm disorder, Atrial
Fibrillation, who were treated with catheter ablation using the NaviStar(R)
ThermoCool(R) Catheter demonstrated significantly better outcomes at one year
compared to those receiving antiarrhythmic drug therapy. In addition, the
patients treated with catheter ablation reported markedly fewer symptoms and
substantially improved quality of life.

“We are proud to offer electrophysiologists so many products and services
focused on catheter ablation, with the aim of helping our customers treat
patients with cardiac arrhythmias,” continued Nachman. “At this year’s Heart
Rhythm, we will be showcasing our market leading product portfolio and
reinforcing our passion for excellence in knowledge, education, and
innovation in the electrophysiology marketplace that we have helped build
over the past 25 years.”

Biosense Webster is committed to ensuring that electrophysiologists have
the information they need to provide optimal ablation diagnosis and therapy
to hundreds of thousands of patients around the world.

“The beauty of our focus in ablation is that we do more than just
arrhythmia management. We offer solutions-real and lasting solutions that can
help doctors change the lives of more and more patients every single day,”
Nachman concluded.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered
electrophysiology diagnostic catheters more than 30 years ago and continues
to lead the industry as an innovative provider of advanced diagnostic,
therapeutic and mapping tools. As the leader in navigation systems and
ablation therapy, Biosense Webster, Inc.’s technology includes the largest
installed base of navigation systems worldwide in leading hospitals and
teaching institutions. With its proprietary products the company is changing
the way electrophysiologists diagnose and treat arrhythmias.

    Ulrike Domany
    Director Public Affairs & Communication EMEA

SOURCE Biosense Webster, Inc.

Source: newswire

comments powered by Disqus